在阿尔茨海默氏病中异常的海马体-皮层-甲-玛相-振幅合
medRxiv : the preprint server for health sciences
|February 23, 2026
概括
阿尔茨海默病 (AD) 破坏了大脑网络协调. 在阿尔茨海默症患者中,海马体-皮质相幅度合 (PAC) 发生变化与认知能力下降相关,这表明PAC是潜在的生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
- 电子生理学 电子生理学
背景情况:
- 阿尔茨海默病 (AD) 的认知衰退可能源于网络功能障碍,而不仅仅是神经元损失.
- 海马-皮质阶段-振幅合 (PAC) 对健康大脑的记忆至关重要.
- 改变静止状态的PAC被假定有助于AD的认知障碍.
研究的目的:
- 在阿尔茨海默病 (AD) 中调查静止状态海马体-皮质PAC的变化.
- 确定海马体-皮质PAC与阿兹海默症患者认知障碍之间的关系.
主要方法:
- 休息状态磁脑电图 (MEG) 数据从78名阿尔茨海默病患者和70名健康对照组中收集.
- 分析了来源重建的海马和皮质信号.
- 反对称双光谱方法量化了非线性跨站点PAC.
主要成果:
- 在阿尔茨海默病患者中观察到海马-皮层PAC的显著干扰,特别是涉及额头,副海马和后皮层.
- 在AD组中,PAC措施与迷你精神状态考试成绩有显著的关联.
- 与对照人群相比,更高的PAC与特定大脑区域的更大的认知障碍相关.
结论:
- 阿尔茨海默氏病的特征是海马体-皮质时间协调发生变化.
- 阶段振幅合 (PAC) 显示出作为AD相关网络功能障碍的电生理学标记物的潜力.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K


